Given the prevalence of obesity and diabetes in the United States and the rapid adoption of GLP-1 agonists it is inevitable that physical therapists will treat patients using medications in this drug class. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.